O Brien Greene & Co. Inc Makes New $206,000 Investment in Cencora, Inc. (NYSE:COR)

O Brien Greene & Co. Inc acquired a new stake in shares of Cencora, Inc. (NYSE:COR) during the second quarter, Holdings Channel reports. The firm acquired 913 shares of the company’s stock, valued at approximately $206,000.

Other hedge funds have also modified their holdings of the company. Rise Advisors LLC bought a new stake in Cencora in the first quarter valued at $25,000. Legacy Bridge LLC bought a new stake in shares of Cencora in the 1st quarter worth about $27,000. New Millennium Group LLC acquired a new stake in shares of Cencora during the 2nd quarter worth about $26,000. TCTC Holdings LLC bought a new position in Cencora during the 1st quarter valued at about $29,000. Finally, TFO Wealth Partners LLC acquired a new position in Cencora in the first quarter valued at about $30,000. 97.52% of the stock is owned by institutional investors and hedge funds.

Cencora Price Performance

Shares of COR opened at $234.53 on Wednesday. The company has a current ratio of 0.89, a quick ratio of 0.55 and a debt-to-equity ratio of 3.93. The stock has a market cap of $46.78 billion, a P/E ratio of 25.66, a price-to-earnings-growth ratio of 1.55 and a beta of 0.44. The stock’s 50-day moving average price is $234.52 and its two-hundred day moving average price is $233.26. Cencora, Inc. has a 1 year low of $177.00 and a 1 year high of $247.66.

Cencora (NYSE:COR) last issued its quarterly earnings data on Wednesday, July 31st. The company reported $3.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.18 by $0.16. The firm had revenue of $74.20 billion during the quarter, compared to analysts’ expectations of $73.32 billion. Cencora had a net margin of 0.65% and a return on equity of 266.60%. The business’s revenue for the quarter was up 10.8% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.92 earnings per share. On average, equities analysts predict that Cencora, Inc. will post 13.63 earnings per share for the current year.

Cencora Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, August 26th. Stockholders of record on Friday, August 9th were given a dividend of $0.51 per share. This represents a $2.04 dividend on an annualized basis and a dividend yield of 0.87%. The ex-dividend date was Friday, August 9th. Cencora’s dividend payout ratio is currently 22.32%.

Insider Buying and Selling

In other Cencora news, EVP Silvana Battaglia sold 1,473 shares of Cencora stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $242.69, for a total value of $357,482.37. Following the transaction, the executive vice president now owns 10,948 shares of the company’s stock, valued at $2,656,970.12. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other Cencora news, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of the business’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $240.56, for a total value of $1,067,646,415.76. Following the sale, the insider now owns 19,980,000 shares in the company, valued at approximately $4,806,388,800. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Silvana Battaglia sold 1,473 shares of the firm’s stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $242.69, for a total transaction of $357,482.37. Following the transaction, the executive vice president now directly owns 10,948 shares of the company’s stock, valued at $2,656,970.12. The disclosure for this sale can be found here. In the last three months, insiders sold 4,450,399 shares of company stock valued at $1,070,392,799. 15.80% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on COR shares. Robert W. Baird dropped their price objective on shares of Cencora from $287.00 to $283.00 and set an “outperform” rating for the company in a report on Friday, September 6th. JPMorgan Chase & Co. lifted their price objective on Cencora from $280.00 to $287.00 and gave the company an “overweight” rating in a research report on Wednesday, August 21st. Wells Fargo & Company increased their target price on Cencora from $236.00 to $249.00 and gave the stock an “equal weight” rating in a report on Thursday, August 1st. Leerink Partners reaffirmed an “outperform” rating and issued a $275.00 price target on shares of Cencora in a report on Thursday, June 27th. Finally, StockNews.com raised shares of Cencora from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 2nd. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Cencora has an average rating of “Moderate Buy” and an average price target of $258.13.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.